Literature DB >> 29706540

Universal Chimeric Antigen Receptors for Multiplexed and Logical Control of T Cell Responses.

Jang Hwan Cho1, James J Collins2, Wilson W Wong3.   

Abstract

T cells expressing chimeric antigen receptors (CARs) are promising cancer therapeutic agents, with the prospect of becoming the ultimate smart cancer therapeutics. To expand the capability of CAR T cells, here, we present a split, universal, and programmable (SUPRA) CAR system that simultaneously encompasses multiple critical "upgrades," such as the ability to switch targets without re-engineering the T cells, finely tune T cell activation strength, and sense and logically respond to multiple antigens. These features are useful to combat relapse, mitigate over-activation, and enhance specificity. We test our SUPRA system against two different tumor models to demonstrate its broad utility and humanize its components to minimize potential immunogenicity concerns. Furthermore, we extend the orthogonal SUPRA CAR system to regulate different T cell subsets independently, demonstrating a dually inducible CAR system. Together, these SUPRA CARs illustrate that multiple advanced logic and control features can be implemented into a single, integrated system.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CAR T therapy; cellular immunotherapy; chimeric antigen receptors; immune cell engineering; synthetic biology; systems biology

Mesh:

Substances:

Year:  2018        PMID: 29706540      PMCID: PMC5984158          DOI: 10.1016/j.cell.2018.03.038

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  67 in total

Review 1.  Improving the efficacy of antibody-based cancer therapies.

Authors:  P Carter
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

2.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

3.  T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.

Authors:  Markus Chmielewski; Andreas Hombach; Claudia Heuser; Gregory P Adams; Hinrich Abken
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

Review 4.  Building better drugs: developing and regulating engineered therapeutic proteins.

Authors:  Chava Kimchi-Sarfaty; Tal Schiller; Nobuko Hamasaki-Katagiri; Mansoor A Khan; Chen Yanover; Zuben E Sauna
Journal:  Trends Pharmacol Sci       Date:  2013-09-20       Impact factor: 14.819

5.  T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.

Authors:  Eugenia Zah; Meng-Yin Lin; Anne Silva-Benedict; Michael C Jensen; Yvonne Y Chen
Journal:  Cancer Immunol Res       Date:  2016-04-08       Impact factor: 11.151

6.  Redirecting gene-modified T cells toward various cancer types using tagged antibodies.

Authors:  Koji Tamada; Degui Geng; Yukimi Sakoda; Navneeta Bansal; Ratika Srivastava; Zhaoyang Li; Eduardo Davila
Journal:  Clin Cancer Res       Date:  2012-10-02       Impact factor: 12.531

7.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Authors:  Marco Ruella; David M Barrett; Saad S Kenderian; Olga Shestova; Ted J Hofmann; Jessica Perazzelli; Michael Klichinsky; Vania Aikawa; Farzana Nazimuddin; Miroslaw Kozlowski; John Scholler; Simon F Lacey; Jan J Melenhorst; Jennifer J D Morrissette; David A Christian; Christopher A Hunter; Michael Kalos; David L Porter; Carl H June; Stephan A Grupp; Saar Gill
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

8.  Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.

Authors:  Xiaojun Liu; Shuguang Jiang; Chongyun Fang; Shiyu Yang; Devvora Olalere; Edward C Pequignot; Alexandria P Cogdill; Na Li; Melissa Ramones; Brian Granda; Li Zhou; Andreas Loew; Regina M Young; Carl H June; Yangbing Zhao
Journal:  Cancer Res       Date:  2015-09-01       Impact factor: 12.701

9.  Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor.

Authors:  Katherine G MacDonald; Romy E Hoeppli; Qing Huang; Jana Gillies; Dan S Luciani; Paul C Orban; Raewyn Broady; Megan K Levings
Journal:  J Clin Invest       Date:  2016-03-21       Impact factor: 14.808

10.  TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy.

Authors:  Zakaria Grada; Meenakshi Hegde; Tiara Byrd; Donald R Shaffer; Alexia Ghazi; Vita S Brawley; Amanda Corder; Kurt Schönfeld; Joachim Koch; Gianpietro Dotti; Helen E Heslop; Stephen Gottschalk; Winfried S Wels; Matthew L Baker; Nabil Ahmed
Journal:  Mol Ther Nucleic Acids       Date:  2013-07-09       Impact factor: 10.183

View more
  176 in total

Review 1.  Recent advances and discoveries in the mechanisms and functions of CAR T cells.

Authors:  Rebecca C Larson; Marcela V Maus
Journal:  Nat Rev Cancer       Date:  2021-01-22       Impact factor: 60.716

Review 2.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

3.  A Universal CAR-NK Cell Targeting Various Epitopes of HIV-1 gp160.

Authors:  Rebecca M Lim; Liang Rong; Anjie Zhen; Jianming Xie
Journal:  ACS Chem Biol       Date:  2020-07-28       Impact factor: 5.100

4.  Circularly permuted LOV2 as a modular photoswitch for optogenetic engineering.

Authors:  Lian He; Peng Tan; Lei Zhu; Kai Huang; Nhung T Nguyen; Rui Wang; Lei Guo; Ling Li; Yuhan Yang; Zixian Huang; Yun Huang; Gang Han; Junfeng Wang; Yubin Zhou
Journal:  Nat Chem Biol       Date:  2021-05-06       Impact factor: 15.040

Review 5.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

Review 6.  Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?

Authors:  Yeison Santamaria-Alza; Gloria Vasquez
Journal:  Inflamm Res       Date:  2021-05-20       Impact factor: 4.575

7.  When de novo-designed protein logics meet CAR-T therapies.

Authors:  Mingqi Xie; Peilong Lu
Journal:  Cell Res       Date:  2020-11       Impact factor: 25.617

Review 8.  CAR T Cell Therapy for Hematological Malignancies.

Authors:  Xin Yang; Gao-Xiang Wang; Jian-Feng Zhou
Journal:  Curr Med Sci       Date:  2019-12-16

9.  Designed protein logic to target cells with precise combinations of surface antigens.

Authors:  Marc J Lajoie; Scott E Boyken; Alexander I Salter; Jilliane Bruffey; Anusha Rajan; Robert A Langan; Audrey Olshefsky; Vishaka Muhunthan; Matthew J Bick; Mesfin Gewe; Alfredo Quijano-Rubio; JayLee Johnson; Garreck Lenz; Alisha Nguyen; Suzie Pun; Colin E Correnti; Stanley R Riddell; David Baker
Journal:  Science       Date:  2020-08-20       Impact factor: 47.728

Review 10.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.